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ABSTRACT 
 
Molecular Basis for Allosteric Control of Escherichia coli Glycerol Kinase  
by Fructose 1,6-Bisphosphate and IIAglc.  (December 2011) 
Shanna Quinn Mayorov, B.S., Chemistry, Bloomsburg University 
Chair of Advisory Committee: Dr. Donald Pettigrew 
 
 There has been progress towards elucidating the mechanism of Escherichia coli 
glycerol kinase (EcGK) control by its allosteric effectors fructose-1,6-bisphosphate 
(FBP) and IIAglc (a member of the phosphoenolpyruvate:glycose phosphotransferase 
system).  Determining the mechanism requires analysis of the interaction between these 
effectors and the substrates of EcGK.  In this study, a structural and kinetic approach 
was used to determine inhibition by both the effectors.  For this work, the use of 
fluorescence anisotropy to observe ligand binding was investigated.  Also, a foundation 
was laid for future NMR experiments with EcGK. 
 For fluorescence studies, E36C EcGK was labeled with fluorescein and tested for 
changes in anisotropy in the presence of different ligands.  To ensure that E36C was an 
appropriate representative of wildtype protein, initial velocity, inhibition, and 
heterotropic coupling assays were performed.  Groundwork for future NMR experiments 
required analyzing substitutions of the native EcGK cysteines by initial velocity and 
inhibition studies. 
 iv 
 By comparing wildtype enzyme and E36C (variant of wildtype with an 
engineered cysteine residue at position 36), it was found that E36C is a suitable 
substitute and was not drastically affected by labeling with fluorescein.  Anisotropy 
values differed upon binding of different ligands and enabled titrations of the enzyme 
substrate complexes with both effectors to obtain dissociation constants.  This supports 
using the stopped-flow method to assess the on- and off- rates of substrates and to obtain 
values for Q coupling.  Furthermore, the results for FBP showed that inhibition by FBP 
is K-type (affects affinity) with respect to ATP and V-type (affects enzyme velocity) 
with respect to ADP.  The findings presented also showed that native cysteine 
substitutions effect some of the catalytic and allosteric parameters of EcGK and would 
be powerful reporters for ligand binding in NMR.  However, the enzymes are unstable 
and new protocols for protein isolation will need to be drafted.    
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NOMENCLATURE 
 
6IAF 6-iodoacetamidofluorescein 
β-Me β-mercaptoethanol 
DHAP Dihydroxyacetone Phosphate 
DMSO Dimethyl Sulfoxide 
DTT Dithiothreitol 
EAB Enzyme/ATP/Gol Ternary Complex 
EcGK E. coli Glycerol Kinase 
EPQ Enzyme/ADP/G3P Ternary Complex 
G3P Sn-Glycerol-3-Phosphate 
Glc Glucose 
Gol Glycerol 
IIAglc Glucose-Specific Phosphocarrier of the PTS System 
IPTG Isopropylthiogalactoside  
NAD(H) Nicotinamide Adenine Dinucleotide 
NADP(H) Nicotinamide Adenine Dinucleotide Phosphate 
PTS Phosphotransferase System 
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
TEA Triethanolamine  
WT Wildtype EcGK 
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CHAPTER I 
INTRODUCTION  
 
Although intensively studied, the molecular basis for allosteric control of 
proteins is poorly understood.  Useful approaches for addressing allosteric regulation of 
proteins include enzyme kinetics and biophysical methods.  By focusing on 
conformational changes at specific loci, these approaches may be used to probe the 
molecular basis for allosteric control.  Escherichia coli glycerol kinase (EcGK) is one 
such system where limited knowledge of allosteric control exists.  The employment of 
the aforementioned methods will be used to understand the basis for allosteric regulation 
of EcGK by examining effects at specific loci.     
EcGK is a member of the sugar kinase/actin/hsp 70 superfamily, sharing some 
structural and catalytic properties with superfamily members (1).  Within the 
superfamily, there is a conserved two domain structure.  Each domain has two 
subdomains denoted IA/IB and IIA/IIB (Figure 1).  The IA/IIA interface forms the 
conserved catalytic site for ATP hydrolysis associated with superfamily function (1).  
This catalytic cleft serves as the binding site for substrates, is formed by a conserved 
βββαβαβα topology in each subdomain, and is suggested to close through a shear motion 
(2) once  substrates  are  bound (1,3-5).  The  divergent  B subdomains form dimers from 
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junction of the IIB subdomains of two monomers.  Interaction between IB subdomains 
of two dimers produces the enzyme tetramer form of EcGK.  In addition to catalytic and 
structural similarities, EcGK and many members of the superfamily are subjects of 
allosteric control.    
Allosteric effectors regulate enzyme catalysis in response to environmental 
stimuli.  In the case of EcGK, the absence of glucose and simultaneous presence of 
glycerol triggers up-regulation of the glycerol kinase gene (glpK) (6-7).  Without the 
presence of an effector, the enzyme catalyzes the rate-limiting step of glycerol 
metabolism by directly transferring the γ-phosphoryl of ATP to glycerol (8-12).  The 
resulting product is Sn-glycerol-3-phosphate (G3P).  G3P is converted to 
dihydroxyacetone phosphate (DHAP), an intermediate in the glycolytic pathway, and 
thus enables continuation of glycolysis.  Glucose introduction to the cellular 
environment diminishes the necessity for glycerol metabolism and allosteric effectors 
inhibit EcGK enzyme catalysis (13-14).   
 
 
 3 
 
Figure 1: Ribbon Diagram of the EcGK Tetramer.  The subunits are labeled as OXYZ.  
Each monomer has a domain I and domain II. The A subdomains form the catalytic cleft 
around ADP in the diagram and the B subdomains form oligomeric interactions between 
O/Y, O/X, Z/Y, and Z/X.  The inhibitors FBP and IIAglc bind to domain I and II, 
respectively.  R369 is the oligomeric domain bridging residue that extends from one 
subunit into the catalytic cleft of the other in the dimer: R369 from the Y subunit 
extends into the O subunit.     
 
Two different allosteric effectors, FBP and IIAglc, control the catalytic activity of 
EcGK by binding to different domains (Figure 1).  Binding to domain I is FBP, an 
intermediate in glycolysis that is a reporter for sugar availability, much like IIAglc.  
IIAglc, a member of the phosphoenolpyruvate:glycose phosphotransferase system (PTS) 
involved in cellular uptake of PTS sugars like glucose, binds to domain II of EcGK (15).  
Availability of PTS sugars reduces phosphorylation of IIAglc histidine 90, enabling IIAglc 
to assume an inhibitory role of glycerol kinase (5,16-17).  Inhibition by allosteric 
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effectors such as FBP and IIAglc is characterized as either V-type or K-type, where 
inhibition is with respect to a change in Vmax or Km, respectively.  The first effector, 
FBP, has been shown to have characteristics of a V-type system (13).  The second 
effector, IIAglc, controls EcGK via V-type inhibition (18).  Since both these effectors 
bind distal to the catalytic site in different domains, the question of how they elicit 
inhibition, and the conformational changes involved, is raised.      
As seen for FBP and IIAglc, allosteric control results from an effector molecule 
binding to one site and changing the function at another (19).  Currently there exist two 
models of allosteric control mechanisms.  The traditional model attributes control to 
conformational changes in quaternary structure that affect binding or catalysis (20-21).  
More recently, exertion of control is being attributed not to global effects, but to 
perturbations of sparse amino acid networks (22-23).  By analyzing conformational 
changes that result from FBP and IIAglc binding, identification of EcGK with one of 
these two models is possible.     
 Analysis of the crystal structures of wildtype EcGK and its variants has not 
elucidated the mode of allosteric control by FBP or IIAglc.   From these crystal 
structures, however, it was proposed in 1993 that control could be attributed to R369, an 
amino acid near the cleft opening that interjects from one subunit into the neighboring 
subunit (Figure 1)(15).  This interjection holds the amino acid within 10Å of the 
nucleotide ADP in the neighboring subunit.  Support for R369 importance in allosteric 
regulation was found in 2009, where truncation to an alanine reduced inhibition by IIAglc 
(18).   
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Based on the above observation, the arginine peg (R369) and its interaction with 
neighboring residues in both domains were inspected.  Two of the three amino acids 
involved in these domain bridging interactions were Q37 and Y39 of domain I.  These 
amino acids are within 3.5Å of the arginine guanidinium group and affect the FBP/IIAglc 
inhibition parameters and the EcGK Michaelis constants.  A previously generated Q37A 
substitution exhibited a decreased Vmax, decreased affinity for IIAglc, decreased affinity 
for FBP, and decreased inhibition by FBP (24).  A previously generated Y39A 
substitution exhibited a decreased Vmax, decreased affinity for ATP and glycerol, 
abolished IIAglc inhibition, and decreased the affinity for FBP (24).      
Position E36 is located on the same small mobile loop as Q37 and Y39 near the 
cleft opening of both the E. coli and E. casseliflavus glycerol kinases (Figure 2).  It has 
been further shown that glycerol binding to E. casseliflavus glycerol kinase induces a 
conformational shift in amino acid positions 36-48 (25).  For EcGK, crystal structures of 
variants sample different conformations in this region, as shown in S58W and G230C 
(26-27).   
It is possible that an E36 variant may further elucidate the role of this loop in 
allosteric control.  The mobile loop containing E36 (Figure 2) is solvent accessible and is 
a prime target for fluorescence studies.  By labeling the engineered cysteine at position 
36 with the fluorescent probe 6IAF, it may be possible to determine the effect of ligand 
binding on conformational changes at this locus from changes in anisotropy or intensity.  
This E36C variant was previously constructed and shown to be specifically labeled by 
6IAF (28).  Since it was recently discovered that binding of ATP affects E36C 
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anisotropy, it is expected that other ligands may affect the fluorescence properties of 
E36C as well (29).  To prepare for these studies, the effects on the catalytic and 
allosteric parameters of the E36C substitution, as well as the effect of labeling at this 
position, was determined.  After determining how the substitution and labeling affect the 
enzyme, the effect of substrate and inhibitor binding on fluorescence was examined. 
A second approach to determining inhibitor effects on substrate binding is by 
NMR spectroscopy.  NMR spectroscopy has been used in the scientific literature to 
analyze molecular motions.  Because of its versatility and capabilities to examine the 
microscopic environment surrounding individual residues, it is an extremely useful tool.  
Until recently, NMR was mainly used to study enzymes less than 35 kDa (30).  E. coli 
glycerol kinase is a tetrameric protein of 56 kDa per subunit, much too large for 
conventional NMR studies.  Recently, however, there have been innovations within the 
field that allow examination of larger structures by using solid state NMR.   This method 
has no inherent limitations on protein size as orientation averaging can be mimicked and 
reduces the effect on tumbling rate.   
To use solid state NMR, many researchers use site specific isotopes and analyze 
the environment around these key points in the protein.  One ideal target for isotope 
labeling is the amino acid cysteine.  There are five native cysteines in EcGK that are 
well distributed throughout the protein (Figure 2).  These residues are potential probes 
for analyzing ligand binding effects on EcGK conformational changes.  If substitutions 
at these positions alter the catalytic or allosteric properties of EcGK, then the affected 
cysteine should be a useful reporter for ligand binding by NMR.  By determining the 
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effects of native cysteine substitutions on the catalytic and allosteric properties of EcGK, 
it is possible to predict which of these loci will report on inhibition. 
 
Figure 2: Crystal Structure Showing Native Cysteines and Position E36.  The image is a 
homodimer with its secondary structure shown in ribbon form and colored pink for α-
helices, orange for β-sheets, and purple for turns.  The ball and stick structure in the 
catalytic cleft of each subunit is an ATP analog.  The five native cysteine residues are 
shown in green on each subunit.  Position E36 is shown in cyan.  This image is from 
PDB: 1GLL.   
 
The above mentioned specific loci in EcGK have the potential to report on ligand 
induced conformational changes.  By labeling an engineered cysteine at E36 with 
 8 
fluorescein it is possible to examine ligand induced structural changes by fluorescence.  
This approach will enable determination of the mechanism of allosteric control for FBP 
and IIAglc by analyzing their effects on substrate binding.  In this study, the effect of the 
E36C substitution is characterized, anisotropy dependence of labeled E36C in the 
individual and simultaneous presence of ligands is assessed, and the applicability of the 
using the native cysteine substitutions as reporters for inhibition is determined 
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CHAPTER II 
SPECIFIC AIMS 
 
The key goals of this work are shown below in order of assessment: 
1.) Determine Effect of the E36C Substitution and Its Labeling on the Catalytic 
and Allosteric Properties of EcGK. 
 
2.) Define the Effect of Ligand Binding on the Fluorescence Properties of 6IAF 
Labeled E36C.   
 
3.) Evaluation of the Potential Use of EcGK Native Cysteines as Probes for 
Ligand Induced Conformational Changes. 
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CHAPTER III 
MATERIALS AND METHODS 
 
Materials 
General.  All chemicals and enzymes, with the exception of E. coli glycerol 
kinase and IIAglc, were purchased from Sigma-Aldrich Chemical Co. (St. Louis 
Missouri), unless specified.  To perform SDS-PAGE, reagents were purchased from 
Thermo Fisher Scientific.  All centrifugations were performed using the Sorvall RC-5B 
Superspeed Centrifuge with the Fiberlite F15S-8X50C rotor at 4oC unless otherwise 
specified.  Sonication was performed using W220-F Sonicator with microtip from Heat 
Systems-Ultrasonics Inc.  All enzyme assays and protein concentration determinations 
were performed using the Beckman UV/VIS DU800 Spectrophotometer.   
Glycerol-3-Phosphate Purification and Concentration Determination.  Glycerol-
3-phosphate (G3P) was purchased as a cyclohexammonium salt.  Exchange of the 
cyclohexammonium salt for sodium was performed on a cation exchange column (1.2 x 
5.7 cm) with AG50W-X4 hydrogen form resin from BioRad.  A total of 0.67 mmol of 
G3P-cyclohexammonium salt was loaded onto the column and eluted using milliQ H2O 
to remove the cyclohexammonium salt.  The first 2 mL of flow through were discarded 
and the subsequent 3 mL collected and tested for G3P concentration.   
To determine the concentration of G3P in the collected 3 mL volume, a set of 0.5 
mL assays composed of “reverse cocktail” (40 mM Triethanolamine-HCl buffer pH 7.0, 
10 mM MgCl2, 14.7 units of glucose-6-phosphate dehydrogenase, 29 units of 
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hexokinase, 2 mM D-glucose, and 0.2mM NADP+), 2.5 mM ADP, and 90 μg/mL EcGK 
were prepared (see the activity scheme in Figure 3).  Each assay was measured for its 
A340 reading before adding any of the G3P solution.  This was recorded as the starting 
point for determining the total change in absorbance.  At this time, a sample of the G3P 
solution was added and the reaction allowed to continue until completion.  One cuvette 
had deionized water added in lieu of G3P and served as the control.  Using Beer’s Law 
and the extinction coefficient of 6.2 mM-1cm-1 for NADPH, the concentration of G3P 
was determined.  This is because one G3P molecule is consumed for every NADPH 
molecule generated.  All measurements were performed on the Beckman UV/VIS 
DU800 Spectrophotometer.       
 
 
 
Figure 3: Representation of Continuous ATP Assay.  The coupling enzymes, HK 
(hexokinase) and G6PD (glucose-6-phosphate dehydrogenase), are added in the enzyme 
assay at 29 units and 14.7 units per 0.5mL, respectively, to enable visualization of the 
reverse reaction from monitoring NADPH levels.  Glc stands for glucose. 
 
Enzyme Purification 
IIA
glc
 Purification.  The protein IIAglc was expressed in E. coli BL21 DE3 cells 
using the pVEX-crr plasmid and purified as previously described (31).  This plasmid 
was provided by Dr. Saul Roseman, Department of Biology, Johns Hopkins University 
(Baltimore MD).  The concentration of the protein was determined by measuring the 
A260 with an extinction coefficient of 1.6 mM-1cm-1 (5).   
GolATPPGADP EcGK   3
PhosphateGlcADPGlcATP HK  6
NADPHgluconatePNADPPhosphateGlc PDG    66 6
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EcGK Purification.  For purification of wildtype EcGK, the protein was 
expressed using either the pHG165 plasmid as previously described (32) or the pET28 
plasmid, which confers kanamycin resistance.  The sample was then sonicated and 
treated with streptomycin sulfate, two treatments of ammonium sulfate, a Q Sepharose 
Fast Flow column (pH 8.0), Source 15Q pH 7.0, and Source 15Q pH 8.0 as described in 
(28,33).  When using the pET28 plasmid, the antibiotic used to select for transformants 
was kanamycin at 50 µg/mL.   
The E36C and cysteine substitutions were all previously constructed using the 
pHG165 plasmid and were isolated as above (28).  E36C went through the above 
mentioned steps and an additional ATP agarose column as previously described (28,33).  
This final column was (1.5 cm x 4 cm) and had an ATP C-8 matrix attachment (catalog: 
A2767).  E36C was eluted by 1 mM ATP in 0.05 M NaCl glpK standard buffer pH 7.0 
(standard buffer composition: 50 mM triethanolamine (TEA), 2 mM glycerol, 1 mM 
EDTA, 2 mM mercaptoethanol, adjusted to either pH 8.0 or 7.0) (34).   
At the end of EcGK purification, the presence of EcGK was confirmed by an 
enzymatic assay and analyzed for purity by SDS-PAGE.  The concentration of EcGK 
was determined by using an extinction coefficient of 1.73 (mg/mL)-1cm-1(33).  Both 
E36C and EcGK were stored as crystalline suspensions in ammonium sulfate and stored 
at 4oC as previously described (35).  
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Initial Velocity, Inhibition, and Coupling Studies 
Enzyme Preparation.  Prior to experimentation, EcGK crystals underwent a 
buffer exchange by passing through a NAP-10 mini-column equilibrated with glpK 
standard buffer pH 7.0 or 0.1 M TEA pH 7.0.  The 0.1 M TEA buffer was used when 
varying glycerol concentration or working with the enzyme/G3P/ADP complex.  
Crystalline EcGK was re-suspended in 1 mL of the chosen buffer from above and loaded 
onto the equilibrated mini-column and the flow-through discarded.  The sample was 
eluted with 1.4 mL of the same buffer used to equilibrate the column and tested for 
protein concentration using an extinction coefficient of 1.73 (mg/mL)-1cm-1(33). 
Enzyme Catalytic Activity Assays (Forward Direction).  Enzyme activity was 
analyzed in the forward direction (ATP/Gol) by monitoring the decrease of NADH 
concentration via ΔA340 with the extinction coefficient 6.2 mM-1cm-1.   Activity is 
measured by a continuous ADP-coupled spectrophotometric assay at pH 7.0 and at 25 
oC, as shown in Figure 4.  Each 0.5 mL assay contains “forward cocktail” (50 mM 
triethanolamine-HCl (TEA) buffer, 5 mM MgCl2, 20 mM KCl, 7.5 units of pyruvate 
kinase, 7.5 units of lactate dehydrogenase, 0.2 mM PEP, 0.2 mM NADH), and 0.5 
μg/mL EcGK.     
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Figure 4: Representation of Continuous ADP Assay.  PK stands for pyruvate kinase, 
LDH stands for lactate dehydrogenase, and Gol is glycerol.  As EcGK converts Gol to 
G3P, ADP is produced.  As the concentration of ADP increases, PK converts it back to 
ATP using PEP.  This reaction serves a two-fold purpose.  First it retains the solution 
concentration of ATP in the cuvette and second it provides pyruvate, which is the 
substrate for LDH.  LDH then converts pyruvate and NADH to lactate and NAD+.  It is 
this conversion that can be visualized on the spectrophotometer.  Therefore, for each 
ATP molecule consumed, one NADH molecule is consumed.   
 
When determining the Michaelis constant for ATP, 10 mM glycerol was added to 
each 0.5 mL assay and ATP was varied from 0.5-100 μM.  Varying the ATP 
concentration up to 100 μM saturates the first of two binding sites on EcGK, which is 
the most accurate for kinetic parameter determination (34).  When determining the 
Michaelis constant for glycerol, 2.5 mM ATP was added to each 0.5 mL assay and 
glycerol was varied from 5-1600 μM.  The assays were initiated by addition of the EcGK 
enzyme to the final concentration of 0.5 μg/mL.  To obtain the Michaelis constants, the 
kinetic data were fit to the Michaelis-Menten equation (Equation 1) by using 
Kaleidagraph (Synergy Software, Reading, PA).  In Equation 1, 0v  is the initial velocity 
at the indicated concentration of ATP, maxV is the maximum velocity of the enzyme at 
saturating substrate,  ATP  is the concentration of ATP, and ATPmK is the Michaelis 
constant for ATP.  The equation can be used for glycerol as well by changing all terms 
containing ATP to glycerol.   
PGADPGolATP EcGK 3 
PyruvateATPPEPADP PK 
 NADLactateNADHPyruvate LDH
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           (1) 
 
Enzyme Catalytic Activity Assays (Reverse Direction).  Enzyme activity was 
analyzed in the reverse direction (ADP/G3P) by monitoring the increase of NADPH 
concentration via ΔA340 with the extinction coefficient of 6.2 mM-1cm-1.   This ATP-
coupled spectrophotometric assay is measured at pH 7.0 and 25 oC, activity scheme is in 
Figure 3.  Each 0.5 mL assay contained the reverse cocktail components and 8.5 μg/mL 
EcGK.       
When determining the Michaelis constant for ADP, 2.5 mM G3P was added to 
each 0.5 mL assay and ADP was varied from 0.1-0.5 mM.  When determining the 
Michaelis constant for G3P, 0.5 mM ADP was added to each 0.5 mL assay and G3P was 
varied from 0.05-0.6 mM.  The assays were initiated by addition of the EcGK enzyme.  
To obtain the Michaelis constants, the kinetic data were fit to Equation 1 above (switch 
out ATP for ADP and Gol for G3P) using the Kaleidagraph Synergy software.   
FBP/IIA
glc
 Inhibition Assays.  All inhibition assays had the same components in 
the 0.5 mL assay as the catalytic assays described above, depending on which direction 
the enzyme was being tested.  Forward direction: forward cocktail, 2.5 mM ATP, 10 
mM glycerol, and EcGK at a final concentration of 0.5 μg/mL.  Reverse direction: 
reverse cocktail, 0.5 mM ADP, 2.5 mM G3P, and EcGK at a final concentration of 8.5 
μg/mL.  The allosteric effector concentrations were varied as shown in the figures.   
 
  ATPmKATP
ATPV
v

 max0
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For FBP inhibition each assay was incubated for 45 minutes with all assay 
components, including EcGK, with the exception of ATP/ADP.  The nucleotide was 
used to initiate the reaction.  For IIAglc inhibition, the enzyme was added to initiate the 
reaction.   
Allosteric inhibition of EcGK is shown in the context of the thermodynamic 
linkage scheme in Figure 5.  The two key allosteric parameters that are defined from this 
scheme are shown in Equations 2 and 3.  The first parameter is W, which describes the 
effect of the inhibitor on the Vmax of the enzyme.  The second parameter is Q, which 
describes the mutual effect of the substrate and the inhibitor on binding.   
Two kinetic parameters elucidated from inhibition studies are K0.5 and W.  These 
parameters are elucidated from the thermodynamic linkage scheme in Figure 5.  K0.5 is 
the apparent dissociation constant for effector binding.  This parameter reflects the Kd 
for IIAglc because IIAglc binding occurs through a single binding event (see Equation 2).  
In this equation, W is the coupling parameter that describes the effect of the inhibitor on 
Vmax for either FBP or IIAglc, 0SA is the specific activity in the absence of inhibitor and 
SA is the specific activity in the saturating presence of inhibitor, 
V  is the maximum 
velocity in the saturating presence of inhibitor, and 0V is the maximum velocity in the 
absence of inhibitor.  The ratio of the SA or Vmax in the saturating presence of inhibitor 
to the SA or Vmax in the absence of inhibitor is W.  When W>1, there is activation by the 
allosteric effector.  When W<1, there is inhibition.  When W=1, there is no allosteric 
effect on Vmax.  This equation can be used for either FBP or IIAglc.  The allosteric 
inhibitor FBP binds to two sites per EcGK tetramer and shows homotropic coupling.  
 17 
Therefore, its K0.5 is not equivalent to Kd and the homotropic coupling is expressed by 
the Hill coefficient (nH) as shown in Equation 3.  In Equation 3, the term Q is the 
coupling parameter that describes the effect of one ligand binding in the presence of 
another, 0AK  = Km for ATP in the absence of the inhibitor,

AK  = Km for ATP in the 
saturating presence of the inhibitor, the 0IIK  = K0.5 for IIA
glc in the absence of 
substrate, IIK  = K0.5 in the saturating presence of substrate, and FBPK  = K0.5 for FBP.  
When Q=1, there is no allosteric coupling, when it is greater than one there is 
cooperative coupling, and if it is less than one it is antagonistic.   
The data from each experiment is therefore fit to these equations using a non-
linear least squares fit with Kaleidagraph Synergy software.  W is the coupling 
parameter that describes the effect of an inhibitor on Vmax and can be used in Equation 4 
to describe the effect of FBP and IIAglc.   
 
 
 18 
 
Figure 5: Thermodynamic Linkage Scheme Depicting Allosteric Coupling Between 
IIAglc and Mg•ATP for EcGK.  The term E represents either the enzyme/glycerol or 
enzyme/G3P complex.  The term A represents either Mg•ATP or Mg•ADP.  0AK  = Km 
for ATP in the absence of the inhibitor and AK  = Km for ATP in the saturating presence 
of the inhibitor.  0IIK  = K0.5 for IIA
glc in the absence of nucleotides and IIK  = K0.5 in the 
saturating presence of nucleotides.  V  is the maximum velocity in the saturating 
presence of IIAglc and 0V is the maximum velocity in the absence of IIAglc.  P is product.  
The structure of the linkage scheme applies for FBP as well. 
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of the enzyme specific activity on the inhibitor concentration was fit to Equation 4 for 
IIAglc inhibition and Equation 5 for FBP inhibition.  W was calculated using Equation 2.  
The terms in Equation 4 are defined as follows:  XSA  is the specific activity at x 
concentration of inhibitor, 0SA is the specific activity in the absence of inhibitor, SA is 
the specific activity in the saturating presence of inhibitor,  X  is the concentration of 
inhibitor, and 5.0K is the concentration of inhibitor that gives fifty percent of the 
maximum inhibition.  This equation can be used to describe IIAglc binding and 
inhibition.  The terms in Equation 5 are defined as follows:  XSA  is the specific activity 
at x concentration of inhibitor, 0SA is the specific activity in the absence of inhibitor, 
SA is the specific activity in the saturating presence of inhibitor,  X  is the 
concentration of inhibitor, and 5.0K is the concentration of inhibitor that gives fifty 
percent of the maximum inhibition.  The term Hn  is the Hill coefficient, which describes 
the effect of homotropic coupling for FBP.  When Hn >1 there is cooperative coupling.  
When Hn <1 there is antagonistic coupling.  When Hn =1 there is no coupling.   
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Heterotropic Coupling.  For this measurement, the concentration of the 
nucleotide was varied at different fixed concentrations of inhibitor in the saturating 
presence of either glycerol or G3P.  Assays were performed to ascertain the extent of 
coupling between nucleotide and allosteric effector binding.  When analyzing coupling 
between FBP/IIAglc and ATP, each 0.5 mL assay contained the forward cocktail 
components, 10 mM glycerol, and 0.5 μg/mL EcGK.  ATP and the allosteric effectors 
FBP and IIAglc were varied as shown in the figures.  Each FBP containing assay was 
incubated with all assay components, including EcGK, for 45 minutes and was initiated 
with ATP.   Each IIAglc containing assay was initiated by adding EcGK. 
 To analyze coupling between FBP/IIAglc and ADP, each 0.5 mL assay contained 
the reverse cocktail components, 2.5 mM G3P, and 8.5 μg/mL EcGK.  ADP and the 
effectors FBP and IIAglc were varied as shown in the figures.   Each FBP containing 
assay was incubated with all assay components, including EcGK, for 45 minutes and 
was initiated with ATP.   Each IIAglc containing assay was initiated by adding EcGK.   
 Coupling parameters were obtained from these initial velocity enzyme kinetics 
studies from fits of the data to Equation 6 (for FBP) and Equation 7 (IIAglc) using the 
EnzFitter program.  The terms are described previously in Figure 5 for both equations 
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E36C Fluorescence Measurements  
Preparing E36C for Labeling.  A small volume of E36C ammonium sulfate 
crystal suspension was diluted to 0.990 mL in Sephacryl Buffer (0.1 M TEA pH 8.0, 2 
mM glycerol).  DTT was added to the sample to a final concentration of 10 mM in 1 mL, 
which was then incubated for thirty minutes at room temperature (this incubation period 
assures that all cysteines are completely reduced for subsequent labeling).  Next, the 
sample was spun at 13,000 rpm for 1 min in a microcentrifuge to remove any precipitate.  
DTT and ammonium sulfate were removed from the sample by purification on a NAP-
10 column pre-equilibrated with Sephacryl buffer.  The flow-through was discarded and 
the sample eluted with 1.4 mL of Sephacryl buffer into a black 1.5 mL microfuge tube.  
The protein concentration was determined by measuring the A280. 
  Labeling of E36C.  After undergoing the buffer exchange described above, ATP 
was added to the sample at a final concentration of 2.5 mM.  This addition of the 
nucleotide is necessary because it affects the conformation of the enzyme and protects 
native cysteines from conjugation with the fluorophore (28).  At this point, 4750 μM 6-
iodoacetamidofluorescein (6IAF) in DMSO was added at a concentration three times 
that of the protein concentration.  The labeling reaction was incubated for 15 min and 
quenched by the addition of 1 μL of 1:10 β-mercaptoethanol (β-Me). Once quenched, the 
sample was concentrated to 1 mL using the Centricon® mini-concentrator by 
centrifugation at 5,000 rpm for 8 min.  The concentrated sample was purified on a NAP-
10 column pre-equilibrated with glpK standard buffer pH 7.0 to remove β-Me, 6IAF, 
and residual ATP.  The flow-through was discarded and sample eluted with 1.4 mL of 
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glpK standard buffer pH 7.0.  The sample was then dialyzed three times: four hours in 1 
L of 0.2 M NaCl glpK standard buffer pH 7.0, overnight in 1 L of 0.1 M TEA pH 7.0, 
and four hours in 1L of 0.1 M TEA pH 7.0.  The dialyzed sample was scanned from 260-
600 nm and the A280 and A492 were recorded.  The two absorbance values were used to 
determine the protein concentration and the stoichiometry of labeling (mol 6IAF/mol 
GK).  Stoichiometries were required to be below 0.12 to prevent homo-FRET during 
fluorescence experiments (28).  The sample was kept in a black microfuge tube at all 
times to protect the fluorophore from degradation.   
 Fluorescence Measurements.  All steady-state anisotropy measurements were 
made at 25 oC using ISS Phoenix/SLM 4800 Spectrofluorometer with Vinci Software 
(2002-2005).  The spectrofluorometer was equipped with Glan-Thompson calcite prism-
type polarizers.  The excitation wavelength used was 485 nm and the emission 
wavelength was collected using a 514.5 nm interference filter.  All anisotropy 
measurements were calculated using by the Vinci software.   
 Equation 8 was used to extract the K0.5 when performing titrations of 6IAF 
labeled E36C with FBP and IIAglc.  The terms used are defined as follows:  Xr   is the 
anisotropy at X concentration of FBP, 0 r  is the anisotropy in the absence of FBP,  
 X is the concentration of FBP used, 5.0K is the concentration of FBP required to reach 
half saturation of the enzyme, and nH is the Hill coefficient.  When looking at the effects 
of IIAglc inhibition, the structure of the equation is the same, except  X and 5.0K    are 
not raised to the nH. 
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CHAPTER IV 
RESULTS 
 
Determining the Effect of the E36C Substitution and Its Labeling On the Catalytic 
and Allosteric Properties of EcGK 
Purification of Wildtype and E36C EcGK. Glycerol kinase was isolated and 
purified from E. coli cells as described previously in the Materials and Methods section.  
Both wildtype and the E36C variant had similar ammonium sulfate solubility and eluted 
at the same position on the Source 15Q pH 8.0 and pH 7.0 columns, and on the Q-
Sepharose Fast Flow column.  SDS-PAGE of the column fractions from wildtype EcGK 
and E36C purification are shown in Figure 6.  As can be seen from the gel images, the 
proteins are substantially homogeneous and were used for later experimentation.   
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           MW E36C    E36C        E36C 
  1    2     3      4       5        6    
 
 
        WT     WT    WT      WT      WT      WT      WT     WT     WT 
           1         2         3         4         5         6         7         8         9 
 
Figure 6: Purified E36C and Wildtype EcGK.  The top gel is an 10% SDS-PAGE of 
E36C fractions after the ATP agarose column.  The molecular weight marker is in lane 
1: 250 kD, 150 kD, 100 kD, 75 kD, 50 kD, 37 kD, 25 kD, 20 kD, and 15 kD. The 
collected fractions are in 2, 4, and 6 and were pooled for future use.  The artifacts in 
lanes 3 and 5 are overflow from the previous lane.  The bottom gel is a 10% SDS-PAGE 
of wildtype EcGK after the Source 15Q column pH 8.0.  Lanes 1 through 9 correspond 
to an individual fraction collected off the column and were all pooled for future use.   
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Wildtype and E36C Initial Velocity Studies.  The kinetic parameters obtained for 
conversion of ATP/glycerol to ADP/G3P and ADP/G3P to ATP/glycerol between 
wildtype EcGK and the variant E36C were compared to ascertain the effect of this 
substitution.  The assays were performed via the ADP and ATP coupling explained in 
the Materials and Methods section.   
 The data presented in this section are for G3P and glycerol Km determination and 
those for ATP and ADP are presented later.  To determine the Km for glycerol, ATP was 
added to 2.5 mM and glycerol varied using the forward cocktail components described 
in the Materials and Methods section. To determine the Km for G3P, ADP was added to 
0.5 mM and G3P varied using the reverse direction cocktail components described 
previously. The dependence of the initial velocity on glycerol and G3P concentration is 
shown in Figures 7 and 8 below.  The kinetic data obtained from these experiments were 
fit using Equation 1 in Kaleidagraph and compared in the table on page 40.   
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Figure 7: E36C Glycerol Dependence.  Each point on the graph indicates an individual 
assay conducted at the indicated glycerol concentration.  The line shows the fit to 
Equation 1.  Each assay was initiated with enzyme that was added to a final 
concentration of 0.5 μg/mL.      
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Figure 8: Wildtype and E36C G3P Dependence.  Each point on the graph indicates an 
individual assay conducted at the indicated G3P concentration.  The lines show the fits 
for each enzyme to Equation 1.  The open circles represent wildtype and the filled circles 
represent E36C.  The lines show the fit to Equation 1.  Each assay was initiated with 
enzyme that was added to a final concentration of 8.5 μg/mL.      
   
FBP Inhibition of Wildtype and E36C.  To characterize the extent of inhibition of 
E36C compared to wildtype, inhibition studies were performed for both enzymes.  The 
activity dependence as a function of FBP concentration for both enzymes is shown 
below in Figures 9 and 10.  The fits were generated using Equation 5 which provided the 
parameters K0.5 and nH.  The parameter W was determined using Equation 2.  The results 
of inhibition of the forward reaction were compared to the published results for FBP (5) 
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and the results of inhibition in the reverse reaction were compared independently in this 
work.  These values were compared in the table on page 40. 
   
0
10
20
30
40
50
1 10 100 1000 10
4
10
5
E36C Inhibition by FBP in the Forward Direction
S
A
, 
U
/m
g
[FBP], M
 
Figure 9: E36C Inhibition by FBP in the Forward Direction.  Each point on the graph 
indicates an individual assay conducted at the indicated FBP concentration.  The line 
shows the fit to Equation 5.  The parameter W was determined using Equation 2.  Each 
assay was incubated for 45 min and initiated with ATP at a final concentration of 2.5 
mM.      
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Figure 10: Wildtype and E36C Inhibition by FBP in the Reverse Direction.  Each point 
on the graph indicates an individual assay conducted at the indicated FBP concentration.  
The open circles represent wildtype and the filled circles represent E36C.  The line 
shows the fit to Equation 5.  The parameter W was determined using Equation 2.  Each 
assay was incubated for 45 min and initiated with ADP at a final concentration of 0.5 
mM. 
 
IIA
glc
 Inhibition of Wildtype and E36C.  To characterize the extent of IIAglc 
inhibition of E36C compared to wildtype, inhibition studies were performed for both 
enzymes.  Activity was analyzed as a function of IIAglc concentration for both enzymes 
and the results are shown in Figures 11 and 12.  The fits were generated using Equation 
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4, which provided the parameter K0.5.  The parameter W was determined using Equation 
2.   The results are compared in the table on page 40. 
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Figure 11: E36C Inhibition by IIAglc in the Forward Direction.  Each point on the graph 
indicates an individual assay conducted at the indicated IIAglc concentration.  The line 
shows the fit to Equation 4.  W was obtained using Equation 2.  Each assay was initiated 
with E36C at a final concentration of 0.5 μg/mL. 
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Figure 12: Wildtype and E36C Inhibition by IIAglc in the Reverse Direction.  Each point 
on the graph indicates an individual assay conducted at the indicated IIAglc 
concentration.  The open circles represent wildtype and the filled circles represent E36C.  
The line shows the fit to Equation 4.  W was obtained using Equation 2.  Each assay was 
initiated with EcGK at a final concentration of 8.5 μg/mL. 
 
Heterotropic Coupling Between FBP and ATP/ADP.  Heterotropic coupling 
assays were performed to see if binding of either of the nucleotides influences binding of 
FBP.  To analyze this question, assays were performed where ATP or ADP were varied 
at different fixed concentrations of FBP.  The fits of the assays that contained ATP are 
shown in Figures 13 and 14.  The solid lines in these figures represent the best fit from 
using Equation 6.  The parameters are compared in the table on page 40. 
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Figure 13: Wildtype FBP and ATP Coupling.  Each point on the graph indicates an 
individual assay conducted at the indicated ATP concentration.  The concentration of 
FBP is 0 μM for the top curve represented by the open circles.  Each curve underneath 
increases in concentration: 15 μM, 30 μM, 45 μM, 91 μM, 185 μM, and 350 μM FBP.  
The lines show the fits to Equation 6.  Each assay was incubated for 45 min and initiated 
with the indicated concentration of ATP. 
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Figure 14: E36C FBP and ATP Coupling.  Each point on the graph indicates an 
individual assay conducted at the indicated ATP concentration.  The concentration of 
FBP is 0 μM for the top curve and is represented by the open circles.  Each curve 
underneath increases in concentration: 15 μM, 30 μM, 45 μM, 91 μM, 185 μM, and 350 
μM FBP.  The lines show the fits to Equation 6.  Each assay was incubated for 45 min 
and initiated with the indicated concentration of ATP. 
 
The fits of the assays that contained ADP are shown in Figures 15 and 16.  The 
solid lines in these figures represent the best fit from using Equation 6.   
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Figure 15: Wildtype FBP and ADP Coupling.  Each point on the graph indicates an 
individual assay conducted at the indicated ADP concentration.  The concentration of 
FBP is 0 μM for the top curve represented by the open circles.  Each curve underneath 
increases in concentration: 15 μM, 30 μM, 45 μM, 91 μM, 185 μM, and 350 μM FBP.  
The lines show the fits to Equation 6.  Each assay was incubated for 45 min and initiated 
with the indicated concentration of ADP. 
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Figure 16: E36C FBP and ADP Coupling.  Each point on the graph indicates an 
individual assay conducted at the indicated ADP concentration.  The concentration of 
FBP is 0 μM for the top curve represented by the open circles.  Each curve underneath 
increases in concentration: 15 μM, 30 μM, 45 μM, 91 μM, and 185 μM FBP.  The lines 
show the fits to Equation 6.  Each assay was incubated for 45 min and initiated with the 
indicated concentration of ADP. 
 
Heterotropic Coupling Between IIA
glc
 and ATP/ADP.  Heterotropic coupling 
assays were performed to see if binding of either of the nucleotides influence inhibition 
by IIAglc.  As with FBP, the assays were performed with varied ATP or ADP 
concentrations at different fixed concentrations of IIAglc.  The fits of the data are shown 
in Figures 17-19.  The solid lines in these figures represent the best fit from using 
Equation 7 and the extracted parameters are summarized in the table on page 40. 
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Figure 17: E36C IIAglc and ATP Coupling.  Each point on the graph indicates an 
individual assay conducted at the indicated ATP concentration.  The concentration of 
IIAglc is 0 μM for the top curve represented by the open circles.  Each curve underneath 
increases in concentration: 1 μM, 2 μM, 5 μM, 10 μM, 20 μM, 30 μM, and 60 μM IIAglc.  
The lines show the fits to Equation 7.  Each assay was initiated with the EcGK at a final 
concentration of 0.5 μg/mL.   
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Figure 18: Wildtype IIAglc and ADP Coupling.  Each point on the graph indicates an 
individual assay conducted at the indicated ADP concentration.  The concentration of 
IIAglc is 0 μM for the top curve represented by the open circles.  Each curve underneath 
increases in concentration: 1 μM, 5 μM, 10 μM, 20 μM, and 40 μM IIAglc.  The lines 
show the fits to Equation 7.  Each assay was initiated with the EcGK at a final 
concentration of 8.5 μg/mL.   
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Figure 19: E36C IIAglc and ADP Coupling.  Each point on the graph indicates an 
individual assay conducted at the indicated ADP concentration.  The concentration of 
IIAglc is 0 μM for the top curve represented by the open circles.  Each curve underneath 
increases in concentration: 1 μM, 5 μM, 10 μM, 20 μM, and 40 μM IIAglc.  The lines 
show the fits to Equation 7.  Each assay was initiated with the EcGK at a final 
concentration of 8.5 μg/mL.   
 
All the parameters extracted from initial velocity, inhibition, and heterotropic 
coupling studies shown above are summarized in Table 1.  The wildtype Km for glycerol 
was taken from previously published data for comparison (5).  The results of E36C 
inhibition by IIAglc in the forward reaction were compared to the published results for 
wildtype inhibition by IIAglc (5) Those of the reverse reaction for both enzymes during 
the IIAglc inhibition studies were compared independently in this work.   
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Table 1: E36C Substitution Effects on EcGK Activity 
  FORWARD REVERSE 
PARAMETER WILDTYPE E36C WILDTYPE E36C 
  Initial Velocity Studies 
Vmax U/mg 50 ± 1b 56 ± 2 2.0 ± 0.2 1.5 ± 0.1 
Km
Gol/G3P, μM 37 ± 4b  27.2 ± 4.4 305 ± 60 246 ± 36 
  FBP Inhibition Studies 
SA0 U/mg 41 ± 2a 49 ± 1 1.9 ± 0.1 1.8 ± 0.1 
K0.5, FBP (μM) 630 ± 90a 478 ± 17 97 ± 4 120 ± 5 
WFBP 0.02 ± 0.05a 0.06 ± 0.01 0.05 ± 0.01 0.11 ± 0.02 
nH 1.6 ± 0.3a 1.7 ± 0.1 1.3 ± 0.1 1.6 ± 0.1 
  IIA
glc
 Inhibition Studies 
SA0 U/mg 36 ± 1a 48 ± 1 1.9 ± 0.1 1.6 ± 0.1 
K0.5, IIA
glc (μM) 6.3 ± 1.0a 11 ± 2 5 ± 1 9 ± 1 
WIIAglc 0.07 ± 0.04a 0.14 ± 0.07 0.16 ± 0.01 0.13 ± 0.05 
  FBP and ATP/ADP Heterotropic Coupling 
Vmax U/mg 15 ± 1 19 ± 1 3.2 ± 0.1 2.2 ± 0.1 
Km 
ATP/ADP, μM 11 ± 1 8 ± 1 304 ± 17 162 ± 1 
K0.5, FBP (μM) 149 ± 29 82 ± 1 89 ± 10 148 ± 2 
WFBP 0.03 ± 0.13 0.01 ± 0.01 0.04 ± 0.03 0.01 ± 0.01 
QFBP 0.6 ± 0.2 0.4 ± 0.1 1.1 ± 0.2 0.8 ± 0.1 
nH 1.3 ± 0.2 1.5 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 
  IIAglc ATP/ADP Heterotropic Coupling 
Vmax U/mg 21 ± 1a 21 ± 1 3.1 ± 0.2 2.1 ± 0.1 
Km 
ATP/ADP, μM 12 ± 2a 8.9 ± 0.5 307 ± 38 151 ± 23 
K0.5, IIA
glc (μM) 7 ± 2a 5.8 ± 1.0 13 ± 4 5.6 ± 2.1 
WIIAglc 0.03 ± 0.02a 0.08 ± 0.01 0.001 ± 0.07 0.05 ± 0.03 
QIIAglc 1.6 ± 0.6a 1.5 ± 0.3 0.74 ± 0.37 1.2 ± 0.6 
a: Values taken from Pettigrew (5) 
b: Values taken from Acquaye (24) 
 
This table compares the parameters for both wildtype and E36C in both the “forward” 
and “reverse” directions.  The forward direction involves going from ATP/Gol to 
ADP/G3P and the revere involves going from ADP/G3P to ATP/Gol.  The Km values for 
the substrates are listed in the left foremost column as KmGol/G3P and KmATP/ADP.  If the 
corresponding value is under the “forward” subheading, the value corresponds to Gol or 
ATP and if under the “reverse” subheading it corresponds to G3P or ADP.  The values 
are reported with their standard errors. 
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The Vmax values for all of the experiments were similar for both wildtype and 
E36C and the initial velocity studies for determining the KmGol and KmG3P for both 
wildtype and E36C yielded similar results for the Km values.  Comparing FBP and IIAglc 
inhibition produced small differences between the two enzymes.   The WFBP in the 
reverse direction was 2-fold higher for E36C than wildtype and the K0.5IIAglc in the 
reverse direction is 2-fold higher for E36C.    From the FBP and ATP heterotropic 
coupling experiments, the K0.5FBP is 2-fold less than wildtype for E36C.  The FBP and 
ADP heterotropic coupling, however, has a 2-fold higher K0.5FBP and 2-fold lower KmADP 
for E36C compared to wildtype.  The only difference between the two enzymes from the 
IIAglc heterotropic coupling assays is that the KmADP is 2-fold less for E36C than 
wildtype.   
6IAF Labeling Effects on FBP and IIA
glc
 Inhibition.  The effect of labeling E36C 
was tested by four different mixtures: untreated, time zero, labeled E (excess), and 
labeled C (clean).  The untreated sample is E36C incubated with 10 mM DTT, purified 
on the NAP-10 column, tested for concentration, and had the ATP addition.  The time 
zero point was a sample of E36C that was incubated for 30 min in Sephacryl buffer with 
10 mM DTT, purified on the NAP-10 column, tested for concentration, and had the ATP 
addition.  The key difference was that 10 μL of 1:10 β-Me was added to the sample 
before 6IAF, thus preventing labeling and creating a time zero sample (which contains 
quenched 6IAF).  The labeled E was a sample that went through all the conventional 
steps and waited for 15 min of labeling before adding the β-Me.  This sample, however, 
was not cleaned on the NAP-10 column or dialyzed after labeling and therefore 
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contained the excess β-Me, ATP, and quenched 6IAF.  The labeled C sample went 
through all conventional steps, including the NAP-10 column and dialysis after labeling, 
removing excess quenched 6IAF.  Each sample was tested for their FBP (Figure 20) and 
IIAglc (Figure 21) inhibition as described in the Materials and Methods section.  The 
concentration of the inhibitor was varied as shown in the figures and the results 
summarized in Table 2.  
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Figure 20: E36C Labeling Effects on FBP Inhibition.  Each point on the graph indicates 
an individual assay conducted at the indicated concentration of FBP.  The filled circles 
represent “untreated”, open squares represent “time zero”, filled squares represent 
“labeled E”, and open triangles represent “labeled C”.  The lines show the fits to 
Equation 5 and the parameters extracted from these fits are presented in Table 2 below.  
Each assay was incubated for 45 min and initiated with ATP at a final concentration of 
2.5 mM. 
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Figure 21: E36C Labeling Effects on IIAglc Inhibition.  Each point on the graph indicates 
an individual assay conducted at the indicated concentration of IIAglc.  The filled circles 
represent “untreated”, open squares represent “time zero”, filled squares represent 
“labeled E”, and open triangles represent “labeled C”.  The lines show the fits to 
Equation 5 and the parameters extracted from these fits are presented in Table 2 below.  
Each assay was initiated with EcGK at a final concentration of 0.5 μg/mL. 
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Table 2: 6IAF Labeling Effects on FBP and IIAglc Inhibition 
  FBP Inhibition 
ENZYME PREP SA0, U/mg K0.5, μM W nH 
Untreated 33 ± 1 617 ± 29 0.13 ± 0.02 1.7 ± 0.1 
Time Zero 35 ± 1 574 ± 19 0.08 ± 0.01 1.4 ± 0.1 
 Labeled E 35 ± 1 650 ± 42 0.09 ± 0.02 1.5 ± 0.1 
Labeled C 33 ± 1 620 ± 16 0.13 ± 0.01 1.8 ± 0.1 
  IIAglc Inhibition 
ENZYME SA0, U/mg K0.5, μM W nH 
Untreated 36 ± 1 6.1 ± 0.8 0.10 ± 0.03 NA 
Time Zero 37 ± 1 4.1 ± 0.3 0.16 ± 0.01 NA 
 Labeled E 37 ± 1 5.8 ± 0.2 0.12 ± 0.01 NA 
Labeled C 33 ± 1 5.8 ± 1.0 0.10 ± 0.01 NA 
These results are from a non-linear least squares fitting of the inhibition data using 
Equations 2 and 3.  This was done with the Kaleidagraph software from Synergy.  The 
parameter W describes the extent of inhibition by IIAglc and is obtained from Equation 2.  
All of these assays were performed in the “forward” direction.  NA is not applicable.  
Values are given with standard errors.  
 
 Although there does exist some slight variation between the treatments, the 
differences are small.  For FBP inhibition, all of the specific activities are comparable, as 
well as the K0.5, W, and nH values.  For IIAglc inhibition, the parameters are again 
comparable between the different treatments.  The largest difference observed is for the 
time zero sample but, due to the closeness of the parameters, it is not statistically 
different from untreated, labeled E, or labeled C.   
6IAF Time Course Study.  To evaluate whether the specific activity of the 
enzyme changes during the labeling process, a time course experiment was conducted 
and the results are shown below in Figure 22.  For this experiment, the sample went 
through all the conventional steps up to adding the 6IAF.  Once labeling was initiated 
with 6IAF, aliquots were removed and quenched with 1 μL of 1:10 β-Me at the time 
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points indicated in the figure.  The assays were composed of the forward cocktail, 2.5 
mM ATP, and 10 mM glycerol.     
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Figure 22: E36C Labeling Effects over Time.  Each point on the graph indicates an 
individual assay conducted at the indicated time to determine if specific activity changes 
during the labeling process.  The slope is 0.01 U mg-1min-1 and the Vmax is 39.0 ± 0.5.  
Each assay was initiated with EcGK at a final concentration of 0.5 μg/mL. 
 
 The pattern of activity in Figure 22 shows a slight increase in activity that returns 
to normal levels over time.  The slope generated from the plot 0.01 U mg-1 min-1 and is 
not significant enough to establish an effect of 6IAF on enzyme activity during the 
labeling process.   
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Defining the Effect of Ligand Binding on the Fluorescence Properties of 6IAF 
Labeled E36C 
Effects of Ligand Binding on Fluorescence.  To determine whether the 
fluorescence properties of the extrinsic fluorophore are altered by ligand binding, a 
variety of ligand combinations were tested.  Only labeled E36C with a stoichiometry of 
0.12 (mol of fluorescein / mol EcGK subunit) or less was used and added to a final 
concentration of 250 nM (subunits).  This low stoichiometry was used since higher 
stoichiometries above 0.12 resulted in Homo-FRET.  When ATP or ADP was part of the 
complex being tested, the final concentration was 5 mM.  When glycerol or G3P were 
part of the complex, the final concentration was 2 mM.   
To assess the possibility of Q-coupling, all complexes were tested in the absence 
and presence of the effectors IIAglc and FBP.  When these effectors were added, IIAglc 
was added to a final concentration of 80 μM and FBP was added to a final concentration 
of 8mM.  Volumes were made up to 1.4 mL for each assay using 0.1 M TEA pH 7.0 and 
allowed to warm up in the spectrophotometer for 5 min, 15 min for samples that 
contained FBP to allow tetramer formation.  All anisotropy values were calculated by 
the Vinci Software program.  The tested complexes and their results are recorded in 
Table 3.  Although both anisotropy and intensity data were recorded, intensity changes 
were less than 10% and thus only anisotropy was considered useful for comparison. 
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Table 3: Effects of Ligand Binding on E36C:6IAF Anisotropy 
 
ALLOSTERIC EFFECTOR 
LIGANDS 
NONE FBP IIA
glc
 
ANISOTROPY ANISOTROPY ANISOTROPY 
None 0.158 ± 0.004 (4) 0.157 ± 0.002 (3) 0.167 ± 0.002 (2) 
ATP 0.167 ± 0.003 (3) 0.166 ± 0.001 (2) 0.189 ± 0.001 (1) 
Glycerol 0.173 ± 0.005 (3) 0.163 ± 0.001 (2) 0.171 ± 0.001 (1) 
ATP/Glycerol 0.200 ± 0.011 (3) 0.164 ± 0.010 (3) 0.174 ± 0.009 (3) 
ADP 0.181 ± 0.003 (3) 0.178 ± 0.004 (2) 0.187 ± 0.004 (2) 
G3P 0.173 ± 0.002 (3) 0.166 ± 0.003 (2) 0.170 ± 0.002 (2) 
ADP/G3P 0.186 ± 0.006 (3) 0.166 ± 0.009 (3) 0.179 ± 0.009 (3) 
Anisotropy values are given as the mean ± standard deviation for the number of trials 
shown in parenthesis.  When the number of trials is 2, the uncertainty is propagated from 
the relative uncertainties of the individual values.  When the number of trials is 1, the 
uncertainty is the value for the individual determination as given by the Vinci software.    
 
 According to the anisotropy values, all substrates increase the anisotropy when 
compared to the enzyme alone by at least 0.009 and the highest increase in anisotropy 
occurs when both ATP and glycerol or ADP and G3P are bound.  FBP addition to each 
of the complexes tested shows that FBP decreases the anisotropy of the 
enzyme/ATP/Gol and enzyme/ADP/G3P ternary complexes.  IIAglc addition increases 
the anisotropy of the enzyme/ATP and enzyme/ATP/Gol complexes.     
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Titration of the Ternary Complexes with Allosteric Effectors. By analyzing how 
the allosteric effectors FBP and IIAglc change the anisotropy of the ternary complexes, 
the K0.5 can be determined.  These values can then be compared to those observed from 
the kinetics assay performed previously.   
 Titrations of the EAB (enzyme/ATP/glycerol) and EPQ (enzyme/ADP/G3P) 
complexes were performed to determine the K0.5 for FBP and IIAglc.  Each 1.4 mL assay 
contained 250 nM subunits of the enzyme and 0.1 M TEA pH 7.0.  All samples were 
incubated in the spectrophotometer for 5 min unless they contained FBP, then they 
incubated for 15 min.  The assays involving the EAB complex contained 2 mM glycerol 
and either 2.5 mM ATP or 100 μM ATP.   Two different concentrations of ATP were 
used because EcGK has two apparent binding sites for ATP.  The first is saturated at 100 
μM ATP and the second is saturated at 2.5 mM ATP.  The titrant in each case was the 
inhibitor and it was varied as shown in the figures.  One trial of each titration is shown as 
a representative of the assay in Figures 23 and 25 for the EAB complex. 
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Figure 23: EAB Anisotropy Dependence on FBP.  EAB is the enzyme/ATP/glycerol 
complex.  Each point on the graph indicates an individual assay conducted at the 
indicated FBP concentration.  The filled circles represent assays performed at 100 μM 
ATP and the open squares represent those performed at 2.5 mM ATP.  The data are 
graphed as a change in anisotropy (Δ<r>) between X μM of FBP and 0 μM of FBP for 
the ternary complex.  The lines show the fits to Equation 8.   
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Figure 24:  EAB Anisotropy Dependence on IIAglc.  EAB is the enzyme/ATP/glycerol 
complex.  Each point on the graph indicates an individual assay conducted at the 
indicated IIAglc concentration.  The filled circles represent assays performed at 100 μM 
ATP and the open squares represent those performed at 2.5 mM ATP.  The data are 
graphed as a change in anisotropy (Δ<r>) between X μM of IIAglc and 0 μM of IIAglc for 
the ternary complex.  The lines show the fits to Equation 8.   
 
 When testing the EPQ complex, the assays contained 2 mM G3P and 2.5 mM 
ADP.  The titrant in each case was again the inhibitor and it was varied as shown in the 
figures.  One trial of each titration is shown as a representative of the assay in Figures 25 
and 26. 
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Figure 25:  EPQ Anisotropy Dependence on FBP.  EPQ is the enzyme/ADP/G3P 
complex.  Each point on the graph indicates an individual assay conducted at the 
indicated FBP concentration and at 2.5 mM ADP.  The data is graphed as a change in 
anisotropy (Δ<r>) between X μM of FBP and 0 μM of FBP for the ternary complex.  
The lines show the fits to Equation 8.   
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Figure 26:  EPQ Anisotropy Dependence on IIAglc.  EPQ is the enzyme/ADP/G3P 
complex.  Each point on the graph indicates an individual assay conducted at the 
indicated IIAglc concentration and at 2.5 mM ADP.  The data is graphed as a change in 
anisotropy (Δ<r>) between X μM of IIAglc and 0 μM of IIAglc for the ternary complex.  
The lines show the fits to Equation 8.   
 
The results for K0.5 and nH (for FBP) are averaged from two trials and 
summarized in Table 4 for both the EAB and EPQ complexes.  Table 4 also summarizes 
the parameters extracted for both complexes in the presence and absence of IIAglc.     
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Table 4: EAB and EPQ Anisotropy Dependence on Allosteric Effectors FBP and IIAglc 
  EAB COMPLEX EPQ COMPLEX 
TITRANT 
-Δ<r> 
max K0.5 nH -Δ<r> max K0.5 nH 
FBP 2.5mM 
ATP/ADP 
0.068 ± 
0.001 346 ± 15 0.9 ± 0.1 
0.032 ± 
0.001 269 ± 10 1.5 ± 0.1 
FBP 100μM 
ATP 
0.064 ± 
0.001 67 ± 3 1.5 ± 0.1       
IIA
glc
 
2.5mM 
ATP/ADP 
0.058 ± 
0.001 23 ± 1 NA 
0.033 ± 
0.002 36±4 NA 
IIA
glc
 
100μM ATP 
0.053 ± 
0.002 21 ± 3 NA       
(EAB=Enzyme/ATP/Glycerol, EPQ=Enzyme/ADP/G3P).  All values presented in this 
table are averages from two independent experiments and are reported with propagated 
uncertainty.  The errors are propagated from the two trials.  The shaded boxes indicate 
that no experiments were performed to assess the effects at 100μM ADP when analyzing 
the EPQ complex.  NA is not applicable.   
 
 K0.5 values for FBP and IIAglc were able to be extracted from the fluorescence 
titrations.  For the FBP titrations, the K0.5 and nH values were attainable for both ATP 
concentrations tested and for ADP.  The K0.5FBP value at 2.5 mM ATP was 3-fold higher 
than the value at 100 µM ATP.  The nH value for 2.5mM ATP was 0.9 and that for 
100µM ATP was 1.5 indicating a difference in FBP homotropic interactions at the 
different ATP concentrations.   
 
Evaluating the Potential Use of EcGK Native Cysteines as Probes for Ligand 
Induced Conformational Changes 
 Cysteine Substitution Effects on EcGK Activity.  The five cysteine mutants 
analyzed were C292S, C255S, C269A, C105S:C112A, and C105S:C112V.  The three 
single cysteine mutants were analyzed after completing the third column purification 
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step (Source 15Q pH 8.0).  The dual cysteine mutants were purified and analyzed by Mr. 
Frank N. Raushel as a crude extract after the ammonium sulfate treatment.   
Each single substitution was tested for its effect on the catalytic and allosteric 
parameters of EcGK.  The dual cysteine substitutions were only tested for effects on 
inhibition.  Both the initial velocity assays and IIAglc inhibition assays were initiated 
with EcGK to a final concentration of 0.5 μg/mL for C292S, 1 µg/mL for C255S and 
C269A, and by addition of 50 µL of ammonium sulfate treated cell lysate for 
C105S:C112A and C105S:C112V.  All assays were performed at 25 oC and pH 7.0 
using the forward cocktail. ATP, glycerol, IIAglc, and FBP were all varied as shown in 
the figures.  The effect on glycerol and ATP dependence for the single substitutions 
(C292S, C255S, and C269A) are shown in Figure 27 and Figure 28, respectively.  The 
data were fit to Equation 1 using Kaleidagraph Synergy software.        
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Figure 27: Cysteine Substitution Effects on Glycerol Dependence.  Each point on the 
graph indicates an individual assay conducted at the indicated glycerol concentration and 
was initiated by the addition of EcGK to a final concentration as described previously.  
The open circles represent C292S, the filled circles represent C255S, and the open 
squares represent C269A.  The lines show the fits to Equation 1. 
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Figure 28: Cysteine Substitution Effects on ATP Dependence.  Each point on the graph 
indicates an individual assay conducted at the indicated ATP concentration and was 
initiated by the addition of EcGK to a final concentration as described previously.  The 
open circles represent C292S, the filled circles represent C255S, and the open squares 
represent C269A.  The lines show the fits to Equation 1.   
 
The effect of the single cysteine substitutions on FBP inhibition are in Figure 29 
for C292S, and Figure 30 for C255S and C269A.  The fits were generated using 
Equation 4 with Kaleidagraph Synergy Software.  
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Figure 29: C292S Substitution Effects on FBP Inhibition.  Each point on the graph 
indicates an individual assay conducted at the indicated FBP concentration.  Each assay 
was incubated for 45 min with EcGK and initiated by the addition of ATP to a final 
concentration of 2.5 mM.  The lines show the fits to Equation 4.   
 58 
0
2
4
6
8
10
12
1 10 100 1000 10
4
10
5
C255S and C269A Substitution Effects on 
FBP Inhibition
S
A
, 
U
/m
g
[FBP], M
 
Figure 30: C255S and C269A Substitution Effects on FBP Inhibition.  Each point on the 
graph indicates an individual assay conducted at the indicated FBP concentration.  Each 
assay was incubated for 45 min with EcGK and initiated by the addition of ATP to a 
final concentration of 2.5 mM.  The open circles represent C255S and the filled circles 
represent C269A.  The lines show the fits to Equation 4. 
 
 
Figures 31 and 32 show the dual cysteine substitution effect on FBP inhibition 
for C105S:C112A and C105S:C112V, respectively.  This fits were generated using 
Kaleidagraph and Equation 4.   
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Figure 31: C105S:C112A Substitution Effect on FBP Inhibition .  Each point on the 
graph indicates an individual assay conducted at the indicated FBP concentration.  Each 
assay was incubated for 45 min with EcGK and initiated by the addition of ATP to a 
final concentration of 2.5 mM.  The lines show the fits to Equation 4.   
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Figure 32: C105S:C112V Substitution Effect on FBP Inhibition.  Each point on the 
graph indicates an individual assay conducted at the indicated FBP concentration.  Each 
assay was incubated for 45 min with EcGK and initiated by the addition of ATP to a 
final concentration of 2.5 mM.  The lines show the fits to Equation 4.   
 
The effect of the substitutions on IIAglc inhibition is in Figure 33 for C292S, 
C255S, and C269A, and Figure 34 for C105S:C112A and C105S:C112V.  These plots 
were again generated using Kaleidagraph and Equation 5.      
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Figure 33: Cysteine Substitution Effects on IIAglc Inhibition.  Each point on the graph 
indicates an individual assay conducted at the indicated IIAglc concentration.  Each assay 
was initiated by the addition of EcGK to a final concentration as described previously.  
The open circles represent C292S, the filled circles represent C255S, and the open 
squares represent C269A.  The lines show the fits to Equation 5.   
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Figure 34: C105S:C112A and C105S:C112V Substitution Effects on IIAglc Inhibition.  
Each point on the graph indicates an individual assay conducted at the indicated IIAglc 
concentration.  Each assay was initiated by the addition of EcGK to a final concentration 
as described previously.  C105S:C112A is represented by the filled circles and 
C105S:C112V is represented by the open circles.  The lines show the fits to Equation 5.   
 
 The results from Figures 27 through 34 are summarized below in Table 5.  These 
parameters were all extracted to determine the effect of cysteine substitutions on the 
activity of EcGK.     
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Table 5: Cysteine Substitution Effects on the Functional Properties of EcGK 
Parameter 
ENZYME 
Wildtype C292S C255S C269A 
C105S: 
C112A 
C105S: 
C112V 
  Glycerol Initial Velocity Studies 
Vmax, 
U/mg 50 ± 1b 45 ± 1 23 ± 1 10 ± 1 ND ND 
Km
Gol, μM 37 ± 4b 60 ± 8 12 ± 2 6 ± 2 ND ND 
  ATP Initial Velocity Studies 
Vmax, 
U/mg 13 ± 5b 16 ± 1 4 ± 1 3 ± 1 ND ND 
Km
ATP
, 
μM 9 ± 2a 18 ± 2 6  ± 1 1.5 ± 0.3 ND ND 
  FBP Inhibition 
SA0, U/mg 41 ± 2a 31 ± 2 12 ± 1 11 ± 1 UTD UTD 
K0.5
FBP
, 
μM 630 ± 90a 804 ± 149 190 ± 18 224 ± 10 423 ± 309 320 ± 22 
WFBP 
0.02 ± 
0.05a 
0.02 ± 
0.10 
0.01 ± 
0.02 
0.02 ± 
0.01 0.3 ± 0.3  0.3 ± 0.1 
nH 1.6 ± 0.3a 1.5 ± 0.5 1.8 ± 0.3 1.6 ± 0.1 0.8 ± 0.2 >2 
  IIA
glc
 Inhibition 
SA0, U/mg 36 ± 1a 51 ± 1 20 ± 1 15 ± 1 UTD UTD 
K0.5 
IIAglc
, 
μM 6.3 ± 1a 5 ± 1 15 ± 1 3 ± 1 25 ± 5 8 ± 1 
WIIAglc 
0.07 ± 
0.04a 
0.06 ± 
0.01 0 0 0.2 ± 0.1 0 
a: Values taken from Pettigrew (5) 
b: Values taken from Acquaye (24) 
 
The table compares the catalytic and functional properties of EcGK for each of the 
cysteine mutants.  ND is not determined and UTD is unable to be determined.  The 
parameters were extracted from fits to Equations 1-5.   
 
   The single cysteine mutants differed on catalytic parameters.  The KmGol is 2-fold 
higher for C292S, 3-fold smaller than wildtype for C255S, and 6-fold lower for C269A.  
For the KmATP, there is a 2-fold difference between wildtype and C292S and a 9-fold 
difference between wildtype and C269A.  As for Vmax, the results were mirrored 
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between the initial velocity studies.  According to the glycerol initial velocity studies, 
C255S Vmax was 2-fold lower than wildtype and C269A Vmax was 5-fold lower than 
wildtype.  According to the ATP initial velocity studies, C255S Vmax was 2-fold lower 
and C269A Vmax was 3-fold lower than wildtype.   
 The inhibition parameters for the single cysteine mutants are also different in 
most cases.  The K0.5FBP is approximately 3-fold different for C255S and C269A 
compared to wildtype.  With respect to IIAglc, only C255S had a 2-fold difference in K0.5 
compared to wildtype.  The W values from IIAglc inhibition are zero for C255S and 
C269A, unlike the W of 0.07 for wildtype.  The WFBP is equivalent between wildtype 
and the single cysteine mutants.   
 Comparison of the dual cysteine mutants was done by analyzing EcGK that had 
only been purified by streptomycin sulfate and ammonium sulfate precipitation.  Since 
the EcGK concentration could not be determined, the plots were generated by analyzing 
a change in A340 over time in the presence of different concentrations of inhibitor.  The 
K0.5FBP value for C105S:C112A was comparable to wildtype and that for C105S:C112V 
was 2-fold lower than wildtype.  The WFBP value for C105S:C112A is indistinguishable 
from wildtype because of the error margins, however, the value for C105S:C112V is at 
least 10-fold higher than wildtype.  Furthermore, the nH for C105S:C112A was close to 1 
and indicates either no homotropic coupling for FBP binding or slightly antagonistic 
coupling.  The K0.5IIAglc was similar between wildtype and C105S:C112V, but it was 4-
fold higher than wildtype for C105S:C112A.  The WIIAglc was 2-fold higher for 
C105S:C112A compared to wildtype and it was a value of zero for C105S:C112V.   
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CHAPTER V 
DISCUSSION 
 
E36C as a Suitable Model for Wildtype EcGK 
The effect of the E36C substitution on the catalytic and allosteric properties of 
EcGK can be assessed from the results presented in Table 1.  Comparison of the 
parameters shows that the substitution does not significantly affect the catalytic or 
allosteric properties of the enzyme.   
Catalytic Parameter Comparison.  The catalytic properties of E36C and wildtype 
EcGK are similar.  In the initial velocity studies performed for determining activity 
dependence on glycerol and G3P concentration, the Vmax for the forward direction was 
larger for E36C by a small amount.  In the reverse direction, the Vmax for E36C is less 
than that for wildtype by a small amount.  The KmGol and KmG3P values for E36C were 
somewhat smaller than those for wildtype.  The heterotropic coupling assays yield 
values for Vmax and KmATP, and those obtained were similar with FBP and with IIAglc.  
The Vmax for the FBP and ATP/ADP coupling assays was larger for E36C in the forward 
direction and smaller in the reverse direction when compared to wildtype.   
Although each set of experiments showed no difference in Vmax between E36C 
and wildtype EcGK, there are differences between the initial velocity and heterotropic 
coupling experiments.  The Vmax in the forward direction was 3-fold larger in the initial 
velocity studies than the heterotropic coupling assays for both E36C and wildtype.  
These effects on Vmax can be attributed to a difference in ATP concentration used for the 
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different experiments.  For the initial velocity studies, the concentration of ATP used 
was 2.5 mM.  For the heterotropic coupling studies, the concentration of ATP used was 
≤100 µM.  In the reverse direction, the initial velocity studies have only a small decrease 
in Vmax compared to the coupling studies for both enzymes.   
Comparison of the catalytic parameters for FBP heterotropic coupling and IIAglc 
heterotropic coupling yields many similarities as well.  The Vmax for E36C in the 
forward direction as well as for wildtype and E36C in the reverse direction is equivalent 
between the FBP heterotropic coupling and IIAglc heterotropic coupling experiments.  
Also similar between the experiments is the KmATP and the KmADP values.  These values 
are all the same for both experiments.  The only difference between the FBP coupling 
and IIAglc coupling experiment is the wildtype Vmax in the forward direction.  Although 
there is less activity in the FBP heterotropic coupling experiment than that for the IIAglc 
experiment, the difference is small.  These results also support similarity between 
wildtype and E36C, as the methods produced parameters that were equivalent.   
The results discussed above show that many of the catalytic parameters are the 
same for both wildtype and E36C and that any differences are small.  Since there are no 
large effects on these parameters, the catalytic properties of EcGK are not significantly 
altered by cysteine substitution of E36.  Thus, it appears that E36C is a fair 
representative of wildtype EcGK catalytic activity.   
Comparing Allosteric Parameters.  The allosteric properties of E36C and 
wildtype EcGK are similar for FBP inhibition as shown in the FBP inhibition studies.  
The specific activity in the absence of inhibitor for the FBP inhibition studies was 
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increased a small amount by the E36C substitution in the forward direction and not 
affected in the reverse direction.  The K0.5FBP is smaller for E36C than wildtype in the 
forward direction and larger for E36C than wildtype in the reverse direction.  These 
differences were nominal.  The WFBP was equivalent between the two enzymes in the 
forward direction and 2-fold higher for E36C than wildtype.  The nH values are similar 
between both enzymes in both directions.  Therefore, this experiment indicates that the 
enzymes are similar with respect to FBP binding and inhibition. 
The allosteric properties of E36C and wildtype EcGK are also similar for the 
IIAglc inhibition studies.  The specific activity in the absence of inhibitor for the IIAglc 
inhibition studies was increased by the E36C substitution in the forward direction and 
decreased by the substitution by a nominal amount in the reverse direction.  As for the 
effect of the substitution on K0.5IIAglc, the E36C value is higher than wildtype by a small 
amount in the forward direction and 2-fold higher in the reverse.  The WIIAglc values are 
equivalent for both enzymes in both directions.  Therefore, the enzymes are similar with 
respect to IIAglc binding and inhibition.   
The results of the heterotropic coupling assays for FBP and IIAglc showed only 
small differences in the parameters for wildtype and E36C.  In the FBP heterotropic 
coupling experiments, the K0.5FBP was decreased by the E36C substitution in the forward 
direction and increased in the reverse.  The parameters W, Q, and nH are equivalent 
between wildtype and E36C in both reaction directions.  In the IIAglc heterotropic 
coupling experiments, the K0.5IIAglc was equivalent between the two enzymes in the 
forward direction and affected by a small amount in the reverse direction.  There is a 
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small increase in WIIAglc for E36C in the forward direction, and the results are 
indistinguishable in the reverse.  These results further support that the enzymes are 
equivalent with respect to FBP/IIAglc binding and inhibition.  
The parameters for E36C and wildtype for the inhibition studies showed no 
drastic effects from the substitution in these experiments, but there are differences 
between the parameters in different experiments.  The specific activity for wildtype FBP 
inhibition in the forward direction was slightly larger than that for IIAglc inhibition in the 
inhibition studies.  This difference can be attributed to using a different enzyme 
preparation for each of these experiments.  However, the specific activity values 
obtained from the inhibition studies for E36C in the forward direction was equivalent 
between the inhibition studies.  Those for wildtype and E36C were also equivalent in the 
reverse direction.     
Comparison of the inhibition and heterotropic coupling studies showed some 
differences in the parameters obtained for FBP inhibition by the different methods.   For 
the forward direction, the K0.5FBP from the inhibition studies is 4-fold higher for wildtype 
and 5-fold higher for E36C than the values from the heterotropic coupling experiments.  
The parameters obtained from the inhibition studies represent K0.5FBP at the saturating 
presence of ATP (2.5mM) and those from the heterotropic coupling assays represent 
K0.5FBP in the absence of ATP, i.e. KFBP∞ and KFBP0, respectively.  ATP concentration as 
the cause of the discrepancy is supported by the Q for FBP and ATP coupling being 
antagonistic (Q<1).  This conclusion is supported by the agreements between the K0.5FBP 
determined from the two experiments in the reverse direction, for which Q=1 for 
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FBP/ADP allosteric coupling.  The WFBP was equivalent between the two experiments 
for wildtype in both directions.  The WFBP for E36C is also similar in both the forward 
and reverse direction because WFBP<<1 for both experiments.  The nH values were all 
equivalent for both enzymes between the experiments with the exception of E36C in the 
reverse direction.  This difference, however, was small.   
Comparison of the inhibition and heterotropic coupling studies showed more 
small differences in the parameters obtained for IIAglc inhibition by the different 
methods.  The K0.5IIAglc was equivalent between the two methods for wildtype in the 
forward direction, 2-fold less for E36C in the forward direction, 2-fold higher for 
wildtype in the reverse direction, and only slightly different for E36C in the reverse 
direction for the heterotropic coupling experiments compared to the inhibition assays.  
The WIIAglc was equivalent between the methods for both wildtype and E36C in the 
forward direction.  The WIIAglc for wildtype in the reverse direction is 2-fold less for the 
coupling experiments compared to the inhibition experiments, and the W for E36C is not 
different between the methods.  The data therefore show that the methods all report 
similar parameters for IIAglc binding and inhibition, providing further support for 
similarity between the enzymes.  
The results discussed above show that many of the allosteric parameters are the 
same for both wildtype and E36C and that any observed differences are small.  These 
differences are 2-fold or less, sometimes overlapping.  Since the errors are represented 
here as standard errors, a 2-fold difference is not large enough to constitute a change in 
the allosteric properties of EcGK.  This, in conjunction with the result from analyzing 
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the catalytic parameters, indicates that E36C is a fair representative of wildtype EcGK 
activity.   
 
Effects of Labeling with Extrinsic Fluorophore on E36C Functional Properties 
One approach to determine the molecular basis for allosteric control in EcGK is 
to monitor ligand binding.  Labeled E36C may be a useful probe for reporting on the 
ligand-dependent conformational changes at the catalytic cleft.  A caveat to using 
labeled E36C is that the labeling by 6IAF may interfere with the functional properties of 
the enzyme due to its large size and hydrophobicity.  To address this issue, effects of 
fluorescein labeling to low stoichiometry on the specific activity and allosteric properties 
were determined.  By considering the data in Table 2 and taking notice of the standard 
errors, it becomes apparent that most of the parameters either overlap or are close to one 
another in value.  Small discrepancies are observed for the time zero and labeled E 
samples compared to the untreated samples.  This is most likely due to the presence of 
quenched fluorophore in the sample since the untreated (no label) and labeled C (NAP-
10 purified) samples had the same parameters.  Since no effect is seen, it is possible that 
there is either no effect from labeling or that the effect is too small to be seen at 0.12 
stoichiometry.  It is possible that higher stoichiometries of label to EcGK subunits may 
amplify differences in the allosteric properties of the enzyme.  This still needs to be 
addressed, however, all stoichiometries used in this work were kept below 0.12 to 
prevent homo-FRET (28) and the similarity between the untreated and labeled C 
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samples indicate that labeling does not visibly alter the functional properties of E36C at 
this stoichiometry.   
The data in Table 2 shows that there is no effect on EcGK function from 6IAF 
labeling, but there are a few discrepancies when comparing the parameters between 
different experiments.  First, the Vmax values from these experiments are smaller than 
those from the earlier initial velocity studies and inhibition studies.  However, the 
enzyme used is from a different preparation date and all the other parameters are 
comparable across the experiments with the exception of WFBP.  This WFBP value 
obtained from this experiment is, however, comparable to the inhibition and heterotropic 
coupling studies previously performed because W<<1 and is only 2-fold higher than 
those from the inhibition studies.  In addition, the rest of the parameters are comparable 
between experiments.   
 
Effects of Catalytic Site and Allosteric Ligands on Fluorescence Anisotropy of 
Fluorescein-Labeled E36C EcGK 
Stopped-flow experimentation is a possible approach for determining FBP and 
IIAglc effects on the on- and off-rates of substrates.  However, this method is only 
applicable if changes in fluorescence properties of the labeled enzyme are observed upon 
ligand binding.  In Table 3, binding of substrates both individually and simultaneously 
affect the anisotropy of labeled E36C.   
The fluorescence anisotropy is changed by substrate binding.  Formation of the 
binary complexes of enzyme with either ATP, Gol, ADP, or G3P increases the 
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anisotropy.  This indicates that the labeled E36C position is reporting on conformational 
effects of substrate binding.  Formation of the ternary complexes of enzyme with either 
ATP and Gol or ADP and G3P increases the anisotropy to a greater extent than the 
binary complexes.  Observation of an increased effect upon formation of the ternary 
complexes suggests that fluorescence is reporting on heterotropic coupling between 
substrates.  This supports the heterotropic coupling between substrates that is indicated 
by the differences between the Michaelis constants and dissociation constants for both 
reaction directions for EcGK (36). 
The fluorescence anisotropy is changed by binding of the allosteric inhibitors.  
Binding of IIAglc to the binary and ternary complexes affects the anisotropy of labeled 
E36C.  IIAglc binding increases the anisotropy of the enzyme/ATP and enzyme/ADP 
binary complexes.  Its effects on the anisotropy of the enzyme/Gol and enzyme/G3P 
binary complexes are not significant.  IIAglc binding decreases the anisotropy for the 
enzyme/ATP/Gol and enzyme/ADP/G3P ternary complexes.  Titration of the EAB 
ternary complex showed that binding of IIAglc is not affected by the concentration of 
ATP (Table 3).   
It was shown that IIAglc inhibition of wildtype EcGK and the variants E478C, 
E478C GVN, R369A, and A65T are all dominated by V-type control (5,18).  For these 
enzymes, the effect of Q coupling for the substrates was approximately 2, indicating that 
binding of IIAglc may be slight cooperative in the presence of ATP, but that its inhibition 
is a predominately Vmax.  An S58W variant that is insensitive to inhibition by FBP 
samples an open conformation visible by x-ray crystallography that brings the γ-
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phosphate of ATP within 4.7Å of the O3 of glycerol (26), leading to the suggestion that 
this open conformation is the active form.  This led to the proposal of FBP and IIAglc 
inhibiting the enzyme by promoting the closed form that creates a distance of 7Ǻ 
between the ATP and glycerol (26).  Since heterotropic coupling is not observed for 
IIAglc and nucleotides, it is possible that IIAglc does not inhibit in this manner or that it 
affects the on- and off-rates of substrates equally.  Titrations of the EAB ternary 
complex with IIAglc and the reported Q values in Table 1 indicate, at most, weak 
coupling to ATP.  It is also interesting to note that binding of IIAglc to the binary 
complexes increased the anisotropy and yet binding to the ternary complex decreases 
anisotropy.  This suggests that coupling is involved in IIAglc binding and since its 
binding does not affect the enzyme/nucleotide binary complexes, it is possible that it 
may be coupled to Gol or G3P binding.   
Binding of FBP to the binary and ternary complexes also affects the anisotropy 
of labeled E36C.  FBP binding decreases the anisotropy of the enzyme/Gol and 
enzyme/G3P binary complexes.  Its effects on the anisotropy of the enzyme/ATP and 
enzyme/ADP binary complexes are small and not significant.  FBP binding decreases the 
anisotropy for the enzyme/ATP/Gol and enzyme/ADP/G3P ternary complexes.  The 
titration of the EAB ternary complex at 2.5mM and 100 µM ATP illustrates a distinctive 
shift in the affinity for FBP binding (Figure 23 and Table 4).  The K0.5FBP is 5-fold larger 
at 2.5mM ATP than at 100 µM ATP.  Also, the nH at 2.5 mM ATP illustrates no FBP 
coupling, in contrast to positive cooperativity observed at 100 µM ATP.   
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Previous studies have shown that FBP displays characteristics of a V-type system 
with respect to glycerol since the inhibition constant for FBP is not dependent on 
glycerol concentration (13).  In 1973, FBP was shown to be non-competitive (37).  The 
experiments performed only used a single concentration of FBP to make the 
determinations.  The results presented here for the fluorescence titrations of the EAB 
ternary complex clearly show antagonistic heterotropic coupling between FBP and ATP.  
This is further supported by the FBP inhibition parameters shown in Table 1 for ATP 
coupling where the Q value is 0.6 ± 0.2 and 0.4 ± 0.1 for wildtype and E36C, 
respectively.  These data indicate that FBP/ATP coupling is antagonistic.  Thus, 
inhibition by FBP in the forward direction is due to K-type inhibition in conjunction 
with V-type inhibition.  As for ADP, its binding is not coupled to FBP according to 
Table 1, but an effect may not be visible because on- and off-rates are effected equally 
for ADP.      
Addressing Q-Coupling Through Fluorescence.  Fluorescence anisotropy can be 
used to determine ligand effects on the substrate on- and off-rates and to elucidate the 
effect of ligands on binding and determine the extent of Q-coupling.  The data in Table 3 
shows that coupling can be performed for FBP and ATP by titrating the enzyme/Gol 
complex with ATP and the enzyme/Gol/FBP complex with ATP.  This also works for 
FBP and Gol coupling by titrating the enzyme/ATP complex with glycerol and then 
titrating the enzyme/ATP/FBP complex with glycerol.  To assess coupling between FBP 
and ADP or FBP and G3P, titrations can be performed as follows: enzyme/G3P titrated 
with ADP and enzyme/G3P/FBP titrated with ADP for FBP/ADP coupling; 
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enzyme/ADP titrated with G3P and enzyme/ADP/FBP titrated with G3P.  The 
applicability of this method is supported by the results shown in Table 4 for FBP binding 
to the EAB ternary complex.  Since it was possible to see antagonistic coupling between 
FBP and ATP, it is possible to determine coupling with other ligands using fluorescence.   
Coupling can also be performed for IIAglc and the substrates.  To assess coupling 
between IIAglc and ATP, ADP, Gol, and G3P, the following titrations can be performed: 
enzyme/Gol titrated with ATP and enzyme/Gol/IIAglc titrated with ATP; enzyme/ATP 
titrated with Gol and enzyme/ATP/IIAglc titrated with Gol; enzyme/G3P titrated with 
ADP and enzyme/G3P/IIAglc titrated with ADP; enzyme/ADP titrated with G3P and 
enzyme/ADP/IIAglc titrated with G3P.   
 The changes in anisotropy for the binary and ternary complexes with and without 
IIAglc show promise for determining Q-coupling by fluorescence.  The only caveat for 
determining Q-coupling for IIAglc and substrates with this method is that the ternary 
complexes in Table 4 show different K0.5 values for IIAglc than those observed from the 
inhibition studies in Table 1.  The IIAglc titration of the EAB ternary complex produces a 
K0.5IIAglc that is 2-fold higher than the value obtained from the IIAglc inhibition studies.  
The IIAglc titration of the EPQ ternary complex produces a K0.5IIAglc that is 4-fold higher 
than the value obtained from the IIAglc inhibition studies.   Although these values are not 
equivalent, they are still similar and may only be different because of the absence of 
Mg2+.  If Mg2+ is the reason for the difference among the data, it would appear as though 
Mg2+ affects IIAglc binding but not FBP.   
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Native Cysteines as Probes for Monitoring EcGK Conformational Changes 
The long term goal for analyzing the effect of the cysteine substitutions is so that 
the cysteines can be identified in an NMR spectrum and be used as reporters of ligand 
binding.  To determine which cysteines are potential reporters, the effects of 
substitutions at these cysteine positions on the catalytic and allosteric properties of 
EcGK were determined.  Since the data show they do elicit some effect on the properties 
of EcGK, it indicates that these positions will report on conformational changes within 
the protein   
 According to the data in Table 3, every parameter from initial velocity and 
inhibition studies is affected by at least one of the mutants analyzed.  Both C292S and 
C269A affected the KmATP and all three single substitutions affected the KmGol.  C255S 
and C269A affected K0.5FBP, the dual substitutions affected WFBP, C255S, C269A and 
C105S:C112A affected K0.5IIAglc, and all but C292S affected WIIAglc.  Thus, all of these 
mutants can theoretically report on ligand binding and have their environmental changes 
monitored by NMR.   
In summary, either C292S or C269A would report on ATP binding and all the 
single substitutions could be used to probe glycerol binding.  C255S and C269A would 
report on FBP binding and the dual mutants would show conformational changes from 
FBP exerting inhibition.  C255S, C269A and C105S:C112A would report on IIAglc 
binding and all the mutants would report on conformational changes from IIAglc 
inhibition (with the exception of C292S).   The only issue with using these proteins is 
their instability.  The single cysteine mutants were only stable for a short time after the 
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third column and the double cysteine mutants would not retain activity if put on the first 
column.  Since the samples would need to be pure and highly concentrated for NMR 
spectroscopy, new protein isolation or purification protocols need to be developed.   
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CHAPTER VI 
CONCLUSIONS 
 
 The results of this study provide new insights into regulation of EcGK by FBP 
and IIAglc  and establish a foundation for probing the mechanism of regulation for this 
novel enzyme.  Inhibition for both directions was characterized as either K-type or V-
type for both FBP and IIAglc.  It was also shown that E36C is a suitable model for 
wildtype activity and that fluorescence can be used to monitor binding of ligands.  
Finally, the results show that the native cysteines will provide structural information that 
may be viewed by shifts in an NMR spectrum.     
 From the heterotropic coupling experiments it is clear that inhibition by IIAglc in 
both the forward and reverse direction can be attributed to V-type inhibition.  As for 
FBP inhibition, the effect is K-type and V-type for the forward direction and V-type for 
the reverse.  These conclusions are further supported by the fluorescence titrations 
explained previously.  
Due to the fluorescence studies, it is now known that changes in the E36 
environment occur upon ligand binding because of the bound fluorophore response.  
Since fluorescence titrations were performed in this work and produced workable K0.5 
values for the inhibitors, there is promise for Q-coupling determination.  Thus, further 
characterization of the on and off rates of substrates and the effect FBP and IIAglc have 
on those rates is now possible by use of stopped-flow.  Most importantly, however, use 
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of E36C provides an amiable alternative to wildtype, enabling a clearer depiction of the 
natural protein’s catalytic process.   
Characterization of the cysteine substitutions provides a platform for studying 
environmental changes in response to ligand association by NMR.  Each of the 
substitutions tested contributes to the study by affecting at least one catalytic and 
allosteric parameter.  Thus, these positions may report upon ligand binding.   
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